Related Experiment Videos
Progress in prion vaccines and immunotherapies
Jennifer K Griffin1, Neil R Cashman
1University of Toronto, Centre for Research in Neurodegenerative Diseases, 6 Queen's Park Crescent West, Toronto, ON M5S3H2, Canada. jennifer.griffin@utoronto.ca.
Expert Opinion on Biological Therapy
|February 16, 2005
Summary
Developing immunotherapy for prion diseases is challenging due to self-tolerance. However, antibodies targeting normal prion protein (PrP) show promise in reducing disease-associated prion conversion, offering hope for future treatments.
Area of Science:
- Neuroscience
- Immunology
- Protein Misfolding Diseases
Background:
- Transmissible spongiform encephalopathies (TSEs) are difficult to treat using immunotherapy.
- Self-tolerance to the prion protein (PrP) hinders antibody development.
- Misfolded PrP (PrPSc) is implicated in the pathogenesis of these protein-only infectious disorders.
Purpose of the Study:
- To explore the potential of immunological treatments for prion diseases.
- To investigate the efficacy of antibodies against PrP isoforms in preventing disease progression.
Main Methods:
- Utilizing antibodies targeting the normal cellular prion protein (PrPC).
- Evaluating the impact of these antibodies on PrP isoform conversion in vitro and in vivo models.
Main Results:
- Antibodies against PrPC demonstrated the ability to reduce or eliminate PrP isoform conversion.
- Ongoing studies are exploring PrPSc-specific epitope targets.
Conclusions:
- Immunotherapy targeting PrP offers a rational approach for treating prion diseases.
- These findings provide hope for developing effective immunotherapies and immunoprophylaxis against TSEs.